765 related articles for article (PubMed ID: 18781879)
1. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
2. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
3. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
4. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
Sundar S; Chakravarty J; Agarwal D; Rai M; Murray HW
N Engl J Med; 2010 Feb; 362(6):504-12. PubMed ID: 20147716
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
[TBL] [Abstract][Full Text] [Related]
6. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
7. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
8. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
[TBL] [Abstract][Full Text] [Related]
10. Ambisome plus miltefosine for Indian patients with kala-azar.
Sundar S; Sinha PK; Verma DK; Kumar N; Alam S; Pandey K; Kumari P; Ravidas V; Chakravarty J; Verma N; Berman J; Ghalib H; Arana B
Trans R Soc Trop Med Hyg; 2011 Feb; 105(2):115-7. PubMed ID: 21129762
[TBL] [Abstract][Full Text] [Related]
11. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
[TBL] [Abstract][Full Text] [Related]
12. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
13. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
14. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
15. Combination Therapy Against Indian Visceral Leishmaniasis with Liposomal Amphotericin B (Fungisome
Goswami RP; Rahman M; Das S; Tripathi SK; Goswami RP
Am J Trop Med Hyg; 2020 Jul; 103(1):308-314. PubMed ID: 32394874
[TBL] [Abstract][Full Text] [Related]
16. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
Sundar S; Jha TK; Thakur CP; Mishra M; Singh VP; Buffels R
Clin Infect Dis; 2003 Sep; 37(6):800-4. PubMed ID: 12955641
[TBL] [Abstract][Full Text] [Related]
17. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
19. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh.
Rahman R; Goyal V; Haque R; Jamil K; Faiz A; Samad R; Ellis S; Balasegaram M; Boer MD; Rijal S; Strub-Wourgaft N; Alves F; Alvar J; Sharma B
PLoS Negl Trop Dis; 2017 May; 11(5):e0005635. PubMed ID: 28558062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
